Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 106 are a BUY (92.98%), 8 are a HOLD (7.02%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 33.56% that have a potential upside of 48.26% achieved within 126 days.
Ross Osborn’s has documented 220 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on XGN, Exagen at 15-May-2025.
Analyst best performing recommendations are on CVRX (CVRX).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$1.5
$0.03 (2.04%)
$2
21 days ago
(25-Jun-2025)
6/6 (100%)
$0.28 (22.95%)
14
Hold
$1.25
$-0.22 (-14.97%)
$2
2 months 1 days ago
(15-May-2025)
7/9 (77.78%)
$0.19 (17.92%)
137
Buy
$1.8
$0.33 (22.45%)
$2.5
2 months 1 days ago
(15-May-2025)
0/3 (0%)
$0.74 (69.81%)
Buy
$3
$1.53 (104.08%)
$3
3 months 6 days ago
(10-Apr-2025)
5/13 (38.46%)
$1.62 (117.39%)
123
Buy
$2
$0.53 (36.05%)
$6
3 months 21 days ago
(25-Mar-2025)
2/5 (40%)
$0.69 (52.67%)
26
Which stock is Ross Osborn is most bullish on?
Which stock is Ross Osborn is most reserved on?
What Year was the first public recommendation made by Ross Osborn?